ESR1 and uterine cancer: ER-positive survivors likely received hormone treatment including tamoxifen, which has been observed to cause uterine cancers that have unfavorable tumor characteristics (i.e., p53-positive, ER-negative, advanced FIGO stage, and higher grade) and a worse prognosis compared to sporadic uterine cancer26–28.